Study Reveals Reduced Stroke Risk with Anticoagulation Post-Brain Bleed

A recent study highlights the benefits of oral anticoagulation (OAC) in patients diagnosed with atrial fibrillation (AF) who have a history of intracranial bleeding. Conducted in Finland, the research found that those receiving OAC experienced significantly lower rates of ischemic stroke (IS) and mortality compared to individuals who did not receive anticoagulation therapy. The findings were published in the journal Neurology on October 21, 2023.

The study analyzed data from 1,502 adults diagnosed with their first episode of AF between 2010 and 2017. These patients, with a median age of 78 years, had experienced intracranial bleeding at least 120 days prior to their AF diagnosis. Participants were divided into three groups based on their anticoagulation treatment 90 days post-diagnosis: 15% were treated with direct oral anticoagulants (DOACs), 29% with warfarin, and 56% received no anticoagulation. The follow-up period extended up to two years, allowing researchers to assess the long-term outcomes of these treatment strategies.

The results showed that after two years, the adjusted absolute risks for IS were 1.9% for DOAC users, 3.1% for warfarin users, and 6.1% for those not on OAC. Risks for intracranial bleeding were 2.7%, 6.5%, and 2.9%, respectively, while the mortality rates from other causes were 10.1%, 15.6%, and 24.6%. Notably, DOAC users exhibited a significantly lower risk of IS and death compared to those not receiving anticoagulation, although the risk for intracranial bleeding remained comparable.

Warfarin users also showed reduced risks for IS and death, but they faced a higher likelihood of recurrent intracranial bleeding. The study emphasized that maintaining a therapeutic range (TTR) of 70% or more while on warfarin was associated with even lower risks for both IS and mortality, underscoring the importance of effective management in anticoagulation therapy.

The implications of this study are significant for clinical practice, as it provides valuable insights for healthcare professionals in tailoring treatment plans for patients with AF and prior brain bleeds. Paula Tiili, a researcher from Helsinki University Hospital, noted the necessity for further studies to identify which patients would benefit most from these treatments while minimizing bleeding risks. As the medical community seeks to refine anticoagulation strategies, these findings could lead to improved patient outcomes in this vulnerable population.